By Josh White
Date: Friday 25 Nov 2022
LONDON (ShareCast) - (Sharecast News) - Omega Diagnostics confirmed the receipt of deferred consideration from the sale of the CD4 business on Friday.
The AIM-traded medical diagnostics company said it had now received the £4m of deferred consideration.
"Accordingly, as of close-of-business on 24 November, Omega held cash balances of £6.5m," the board said in its short statement.
At 1116 GMT, shares in Omega Diagnostics Group were up 10.83% at 3.99p.
Reporting by Josh White for Sharecast.com.
Email this article to a friend
or share it with one of these popular networks:
Currency | UK Pounds |
Share Price | 3.75p |
Change Today | 0.000p |
% Change | 0.00 % |
52 Week High | 4.35 |
52 Week Low | 1.73 |
Volume | 869,882 |
Shares Issued | 237.95m |
Market Cap | £8.92m |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
No dividends found |
Time | Volume / Share Price |
15:47 | 221,037 @ 3.62p |
16:27 | 9,623 @ 3.55p |
15:46 | 102 @ 3.92p |
14:32 | 9,500 @ 3.66p |
13:49 | 100,000 @ 3.90p |
You are here: research